The role of BRCA1/2 in hereditary and familial breast and ovarian cancers-Reference-Cited by-同舟云学术

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers

Published:2019-07-17 Issue:9 Volume:7 Page:
ISSN:2324-9269
Container-title:Molecular Genetics & Genomic Medicine
language:en
Short-container-title:Mol Genet Genomic Med

Author:

Hawsawi Yousef M.¹²^ORCID,Al‐Numair Nouf S.²³,Sobahy Turki M.¹,Al‐Ajmi Areej M.³,Al‐Harbi Raneem M.¹,Baghdadi Mohammed A.¹,Oyouni Atif A.⁴,Alamer Osama M.⁴

Affiliation:

1. Research Center King Faisal Specialist Hospital and Research Center Jeddah Kingdom of Saudi Arabia

2. College of Medicine Al‐Faisal University Riyadh Kingdom of Saudi Arabia

3. Department of Genetics, Research Center King Faisal Specialist Hospital and Research Center Riyadh Kingdom of Saudi Arabia

4. Department of Biology, Faculty of Sciences University of Tabuk Tabuk Kingdom of Saudi Arabia

Publisher

Wiley

Subject

Genetics(clinical),Genetics,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mgg3.879

Reference60 articles.

1. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

2. BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes

3. The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin

4. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer

5. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2;Critical Reviews in Oncology/Hematology;2024-09

2. Advancements in targeting tumor suppressor genes (p53 and BRCA 1/2) in breast cancer therapy;Molecular Diversity;2024-08-17

3. The known and unknown about attention deficit hyperactivity disorder (ADHD) genetics: a special emphasis on Arab population;Frontiers in Genetics;2024-08-06

4. Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple‐negative breast cancer;Clinical Case Reports;2024-04

5. Animal Models for Cancer;Animal Models In Experimental Medicine;2024-02-01